Andrx Fortamet Paragraph IV Certifications
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval of Andrx' Fortamet (metformin extended-release) could be delayed by the company's newly filed Paragraph IV certifications against Bristol-Myers Squibb'sGlucophage XR patents